Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB (OMX: IRLAB-A) receives EMA waiver for mesdopetam paediatric studies
Published by Arron Aatkar, PhD

IRLAB has announced that it has received a waiver from the European Medicines Agency, which means it does not have to perform studies of its lead asset, mesdopetam, in children. This would otherwise have been mandatory to support a European marketing authorisation application. Consequently, IRLAB can now focus its efforts in patient groups where Parkinson’s disease (PD) is more prevalent, such as in older populations, and hence avoid resource-demanding and lengthy studies in the paediatric population.

Mesdopetam is IRLAB’s lead clinical candidate, which is being developed as a potential treatment for levodopa-induced dyskinesias in PD patients. The company is currently preparing for Phase III.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free